ETOPOSIDE
Bone Marrow Diseases
National Heart, Lung, and Blood Institute (NHLBI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Bone Marrow Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Clofarabine National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 | CC |
DEXAMETHASONE National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 | CC |
Decitabine Novartis Pharmaceuticals | Phase 1 | CC |
cc-5013 National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 | CC |
Azacitidine Novartis Pharmaceuticals | Phase 1 | CC |
Spartalizumab Novartis Pharmaceuticals | Phase 1 | CC |
Sabatolimab Novartis Pharmaceuticals | Phase 1 | C |
Same molecule, other indications
ETOPOSIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →